Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-06-17

Clinical Trial Update: A Study of Replagal in Treatment-naïve Adults With Fabry Disease [Phase 3]

View source ↗

Summary

This clinical trial update reports that the Phase 3 study of Replagal (agalsidase alfa) in treatment-naïve adults with Fabry disease was terminated, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Replagal (agalsidase alfa)

Snippet

Sponsor: Shire | Conditions: Fabry Disease | Phase 3 | Status: TERMINATED | Results posted: 2024-06-17